GRI Bio (GRI) Revenue & Revenue Breakdown
GRI Bio Revenue Highlights
Latest Revenue (Y)
$21.77M
Latest Revenue (Q)
$4.91M
GRI Bio Revenue by Period
GRI Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $21.77M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $100.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
GRI Bio generated $21.77M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
GRI Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-01-31 | $4.91M | 100.00% |
| 2024-10-31 | - | 100.00% |
| 2024-07-31 | - | 100.00% |
| 2024-04-30 | - | -100.00% |
| 2024-01-31 | $5.39M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | - |
GRI Bio generated $4.91M in revenue during Q4 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
GRI Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FHTX | Foghorn Therapeutics | $22.60M | $2.86M |
| GRI | GRI Bio | $21.77M | $4.91M |
| IMNM | Immunome | $9.04M | $2.93M |
| TNON | Tenon Medical | $3.28M | $770.00K |
| HOWL | Werewolf Therapeutics | $1.89M | - |
| BDRX | Biodexa Pharmaceuticals | $381.00K | $41.50K |
| CLNN | Clene | $342.00K | $91.00K |
| IKNA | Ikena Oncology | - | - |
| TVGN | Tevogen Bio | - | $396.59K |